Please login to the form below

Not currently logged in
Email:
Password:

Lars Dreiøe joins Sobi in senior quality and compliance role

Moves to the Swedish rare diseases company from Denmark's ALK

Sobi Lars DreioeSwedish rare diseases company Sobi has appointed Lars Dreiøe as senior vice president chief quality and compliance officer.

He will join the firm in January from Danish allergy vaccine company ALK Abelló, where he was international head of quality.

Geoffrey McDonough, president and CEO at Sobi, said: "Sobi has been expanding the scope and geographic area of operations and the demands and complexity of external regulations governing our business has also increased.

“Lars will sustain and deepen our global commitment to quality in all aspects of our work, and will be a valuable addition to our senior leadership team."

Dreiøe has 20 years of experience in the biotech and pharmaceutical industries in quality, manufacturing, product safety and regulatory affairs.

He started his industry career with Lundbeck as a production chemist and subsequently held senior roles with Novo Nordisk.

24th December 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health

Cello Health are expert navigators, helping healthcare clients uncover hidden insights, explore scientific options and make difficult strategic choices...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics